Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Pharmanex v. FDA

This article was originally published in The Tan Sheet

Executive Summary

Pharmanex v. FDA: Agency files April 29 motion to dismiss the Pharmanex request for a federal court declaratory judgment that Cholestin cholesterol reduction claims are acceptable under the Dietary Supplement Health & Education Act and that FDA should not take regulatory action against the product as a drug. The agency argues that the complaint should be dismissed because the court lacks "subject matter jurisdiction" and because it seeks to preempt a possible enforcement action based on an informal position taken by FDA in a meeting and thus the matter is not "ripe for review." The complaint was filed in Salt Lake City, Utah federal court April 7 ("The Tan Sheet" April 14, p. 1)...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087033

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel